Show simple item record

dc.contributor.authorSarmiento-Castro, Aida
dc.contributor.authorCaamaño-Gutiérrez, E
dc.contributor.authorSims, Andrew H
dc.contributor.authorHull, N J
dc.contributor.authorJames, M
dc.contributor.authorSantiago-Gómez, Angélica
dc.contributor.authorEyre, Rachel
dc.contributor.authorClark, Christopher
dc.contributor.authorBrown, M. E.
dc.contributor.authorBrooks, M. D.
dc.contributor.authorWicha, M. S.
dc.contributor.authorHowell, Sacha J
dc.contributor.authorClarke, Robert B
dc.contributor.authorSimões, Bruno M
dc.date.accessioned2020-08-17T07:21:40Z
dc.date.available2020-08-17T07:21:40Z
dc.date.issued2020en
dc.identifier.citationSarmiento-Castro A, Caamano-Gutierrez E, Sims AH, Hull NJ, James MI, Santiago-Gomez A, et al. Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH(+) Breast Cancer Stem Cells. Stem Cell Reports. 2020;15(2):307-16.en
dc.identifier.pmid32707076en
dc.identifier.doi10.1016/j.stemcr.2020.06.020en
dc.identifier.urihttp://hdl.handle.net/10541/623198
dc.description.abstractEstrogen-receptor-positive breast tumors are treated with anti-estrogen (AE) therapies but frequently develop resistance. Cancer stem cells (CSCs) with high aldehyde dehydrogenase activity (ALDH+ cells) are enriched following AE treatment. Here, we show that the interleukin-1? (IL-1?) signaling pathway is activated in ALDH+ cells, and data from single cells reveals that AE treatment selects for IL-1 receptor (IL1R1)-expressing ALDH+ cells. Importantly, CSC activity is reduced by an IL1R1 inhibitor in AE-resistant models. Moreover, IL1R1 expression is increased in the tumors of patients treated with AE therapy and predicts treatment failure. Single-cell gene expression analysis revealed that at least two subpopulations exist within the ALDH+ population, one proliferative and one quiescent. Following AE therapy the quiescent population is expanded, which suggests CSC dormancy as an adaptive strategy that facilitates treatment resistance. Targeting of ALDH+IL1R1+ cells merits testing as a strategy to combat AE resistance in patients with residual disease. Keywords: ALDH(+) cells; IL1R1; anti-estrogens; breast cancer stem cells; dormancy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.stemcr.2020.06.020en
dc.titleIncreased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH(+) breast cancer stem cellsen
dc.typeArticleen
dc.contributor.departmentManchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchesteren
dc.identifier.journalStem Cell Reportsen
dc.description.noteen]
refterms.dateFOA2020-08-17T12:35:36Z


Files in this item

Thumbnail
Name:
32707076.pdf
Size:
2.165Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record